Phosphorylated Crkl reduction levels are associated with the lowest P-glycoprotein activity levels in cells from chronic myeloid leukemia patients.

作者: Flavia Cunha Vasconcelos , Gabriela Nestal de Moraes , Arthur Moellmann-Coelho , Raquel Ciuvalschi Maia

DOI: 10.1016/J.LEUKRES.2013.09.021

关键词:

摘要: Abstract ABCB1/P-glycoprotein (Pgp) and ABCG2/BCRP overexpression have been described as related to imatinib resistance in chronic myeloid leukemia (CML). We showed CML cells from 55 patients that Pgp activity was more frequently detected than BCRP (p = 0.0074). Imatinib-induced Crkl phosphorylated protein (pCrkl) reduction pronounced K562 (Pgp-negative) K562-Lucena (Pgp-positive) cell line. Expressive pCrkl levels after vitro treatment observed samples exhibiting lower compared with higher (p = 0.0045). association might help distinguish between imatinib-resistant imatinib-sensitive cells.

参考文章(47)
Chie Hirayama, Hiroshi Watanabe, Reiko Nakashima, Takeru Nanbu, Akinobu Hamada, Akihiko Kuniyasu, Hitoshi Nakayama, Tatsuya Kawaguchi, Hideyuki Saito, Constitutive Overexpression of P-glycoprotein, Rather than Breast Cancer Resistance Protein or Organic Cation Transporter 1, Contributes to Acquisition of Imatinib-Resistance in K562 Cells Pharmaceutical Research. ,vol. 25, pp. 827- 835 ,(2008) , 10.1007/S11095-007-9376-3
Antonio Porro, Nunzio Iraci, Simona Soverini, Daniel Diolaiti, Samuele Gherardi, Carolina Terragna, Sandra Durante, Emanuele Valli, Thea Kalebic, Roberto Bernardoni, Chiara Perrod, Michelle Haber, Murray D. Norris, Michele Baccarani, Giovanni Martinelli, Giovanni Perini, c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells Molecular Cancer Research. ,vol. 9, pp. 1054- 1066 ,(2011) , 10.1158/1541-7786.MCR-10-0510
François-Xavier Mahon, Francis Belloc, Valérie Lagarde, Claudine Chollet, François Moreau-Gaudry, Josy Reiffers, John M. Goldman, Junia V. Melo, MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. ,vol. 101, pp. 2368- 2373 ,(2003) , 10.1182/BLOOD.V101.6.2368
Flavia C. Vasconcelos, Karina L. Silva, Paloma Silva de Souza, Luiz Felipe R. Silva, Arthur Moellmann-Coelho, Claudete E. Klumb, Raquel Ciuvalschi Maia, Variation of MDR Proteins Expression and Activity Levels According to Clinical Status and Evolution of CML Patients Cytometry Part B-clinical Cytometry. ,vol. 80, pp. 158- 166 ,(2011) , 10.1002/CYTO.B.20580
Herman Burger, Hans van Tol, Antonius W. M. Boersma, Mariël Brok, Erik A. C. Wiemer, Gerrit Stoter, Kees Nooter, Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump Blood. ,vol. 104, pp. 2940- 2942 ,(2004) , 10.1182/BLOOD-2004-04-1398
Daniela Cilloni, Giuseppe Saglio, Molecular pathways: BCR-ABL. Clinical Cancer Research. ,vol. 18, pp. 930- 937 ,(2012) , 10.1158/1078-0432.CCR-10-1613
Robert W. Robey, Kenneth Steadman, Orsolya Polgar, Kuniaki Morisaki, Margaret Blayney, Prakash Mistry, Susan E. Bates, Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition Cancer Research. ,vol. 64, pp. 1242- 1246 ,(2004) , 10.1158/0008-5472.CAN-03-3298
Laura N. Eadie, Verity A. Saunders, Timothy P. Hughes, Deborah L. White, Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2 Leukemia & Lymphoma. ,vol. 54, pp. 569- 578 ,(2013) , 10.3109/10428194.2012.715345
Stephanie G. Willis, Thoralf Lange, Shadmehr Demehri, Sandra Otto, Lucy Crossman, Dietger Niederwieser, Eric P. Stoffregen, Shannon McWeeney, Ines Kovacs, Byung Park, Brian J. Druker, Michael W. Deininger, High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. ,vol. 106, pp. 2128- 2137 ,(2005) , 10.1182/BLOOD-2005-03-1036